Global GPCR-targeting Drug Market Growth (Status and Outlook) 2023-2029

Global GPCR-targeting Drug Market Growth (Status and Outlook) 2023-2029

The global GPCR-targeting Drug market size is projected to grow from US$ 393.3 million in 2022 to US$ 473.8 million in 2029; it is expected to grow at a CAGR of 2.7% from 2023 to 2029.

United States market for GPCR-targeting Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for GPCR-targeting Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for GPCR-targeting Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key GPCR-targeting Drug players cover PerkinElmer, Thermo Fisher Scientific, Merck, BD Biosciences, Molecular Devices, Promega, Qiagen, Abcam and Corning, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

GPCRs or G protein-coupled receptors are proteins located on the cell surface that recognize extracellular substances and transmit signals across the cell membrane. GPCRs do this by activating guanine nucleotide-binding proteins (G protein) that are responsible for signal transduction inside the cell. The signal delivery is very important in various cellular responses including cell growth, gene transcription, post-translational changes, and communication with other cells. This brings on adjustments in the body to adapt to the environmental changes such as increased heart rate when feeling threatened or change in vision in response to dim light.

LPI (LP Information)' newest research report, the “GPCR-targeting Drug Industry Forecast” looks at past sales and reviews total world GPCR-targeting Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected GPCR-targeting Drug sales for 2023 through 2029. With GPCR-targeting Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GPCR-targeting Drug industry.

This Insight Report provides a comprehensive analysis of the global GPCR-targeting Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GPCR-targeting Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GPCR-targeting Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GPCR-targeting Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GPCR-targeting Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of GPCR-targeting Drug market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Reagent Test Kit
Substrate

Segmentation by application
Oncology
Cardiovascular
Central Nervous
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
PerkinElmer
Thermo Fisher Scientific
Merck
BD Biosciences
Molecular Devices
Promega
Qiagen
Abcam
Corning
Discoverx
Cisbio

Please note: The report will take approximately 2 business days to prepare and deliver.